Literature DB >> 15606516

Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome.

M B Ericson1, C Sandberg, B Stenquist, F Gudmundson, M Karlsson, A-M Ros, A Rosén, O Larkö, A-M Wennberg, I Rosdahl.   

Abstract

BACKGROUND: Although photodynamic therapy (PDT) is becoming an important treatment method for skin lesions such as actinic keratosis (AK) and superficial basal cell carcinoma, there are still discussions about which fluence rate and light dose are preferable. Recent studies in rodents have shown that a low fluence rate is preferable due to depletion of oxygen at high fluence rates. However, these results have not yet been verified in humans.
OBJECTIVES: The objective was to investigate the impact of fluence rate and spectral range on primary treatment outcome and bleaching rate in AK using aminolaevulinic acid PDT. In addition, the pain experienced by the patients has been monitored during treatment. PATIENTS/
METHODS: Thirty-seven patients (mean age 71 years) with AK located on the head, neck and upper chest were treated with PDT, randomly allocated to four groups: two groups with narrow filter (580-650 nm) and fluence rates of 30 or 45 mW cm(-2), and two groups with broad filter (580-690 nm) and fluence rates of 50 or 75 mW cm(-2). The total cumulative light dose was 100 J cm(-2) in all treatments. Photobleaching was monitored by fluorescence imaging, and pain experienced by the patients was registered by using a visual analogue scale graded from 0 (no pain) to 10 (unbearable pain). The primary treatment outcome was evaluated at a follow-up visit after 7 weeks.
RESULTS: Our data showed a significant correlation between fluence rate and initial treatment outcome, where lower fluence rate resulted in favourable treatment response. Moreover, the photobleaching dose (1/e) was found to be related to fluence rate, ranging from 4.5 +/- 1.0 J cm(-2) at 30 mW cm(-2), to 7.3 +/- 0.7 J cm(-2) at 75 mW cm(-2), indicating higher oxygen levels in tissue at lower fluence rates. After a cumulative light dose of 40 J cm(-2) no further photobleaching took place, implying that higher doses are excessive. No significant difference in pain experienced by the patients during PDT was observed in varying the fluence rate from 30 to 75 mW cm(-2). However, the pain was found to be most intense up to a cumulative light dose of 20 J cm(-2).
CONCLUSIONS: Our results imply that the photobleaching rate and primary treatment outcome are dependent on fluence rate, and that a low fluence rate (30 mW cm(-2)) seems preferable when performing PDT of AK using noncoherent light sources.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15606516     DOI: 10.1111/j.1365-2133.2004.06211.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  19 in total

1.  A prospective study of pain control by a 2-step irradiance schedule during topical photodynamic therapy of nonmelanoma skin cancer.

Authors:  Nathalie C Zeitouni; Ulas Sunar; Daniel J Rohrbach; Anne D Paquette; David A Bellnier; Yi Shi; Gregory Wilding; Thomas H Foster; Barbara W Henderson
Journal:  Dermatol Surg       Date:  2014-12       Impact factor: 3.398

2.  Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy.

Authors:  Theresa M Busch; Xiaoman Xing; Guoqiang Yu; Arjun Yodh; E Paul Wileyto; Hsing-Wen Wang; Turgut Durduran; Timothy C Zhu; Ken Kang-Hsin Wang
Journal:  Photochem Photobiol Sci       Date:  2009-10-15       Impact factor: 3.982

3.  Review of Neurosurgical Fluorescence Imaging Methodologies.

Authors:  Brian W Pogue; Summer Gibbs-Strauss; Pablo A Valdés; Kimberley Samkoe; David W Roberts; Keith D Paulsen
Journal:  IEEE J Sel Top Quantum Electron       Date:  2010-05       Impact factor: 4.544

4.  δ-Aminolevulinic acid and its methyl ester induce the formation of Protoporphyrin IX in cultured sensory neurones.

Authors:  B Novak; R Schulten; H Lübbert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-25       Impact factor: 3.000

5.  Assessing daylight & low-dose rate photodynamic therapy efficacy, using biomarkers of photophysical, biochemical and biological damage metrics in situ.

Authors:  Ana Luiza Ribeiro de Souza; Ethan LaRochelle; Kayla Marra; Jason Gunn; Scott C Davis; Kimberley S Samkoe; M Shane Chapman; Edward V Maytin; Tayyaba Hasan; Brian W Pogue
Journal:  Photodiagnosis Photodyn Ther       Date:  2017-10-14       Impact factor: 3.631

Review 6.  Interventions for actinic keratoses.

Authors:  Aditya K Gupta; Maryse Paquet; Elmer Villanueva; William Brintnell
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

7.  Prostate PDT dosimetry.

Authors:  Timothy C Zhu; Jarod C Finlay
Journal:  Photodiagnosis Photodyn Ther       Date:  2006-10-19       Impact factor: 3.631

Review 8.  Pain associated with aminolevulinic acid-photodynamic therapy of skin disease.

Authors:  Christine B Warren; Laszlo J Karai; Allison Vidimos; Edward V Maytin
Journal:  J Am Acad Dermatol       Date:  2009-12       Impact factor: 11.527

9.  Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas.

Authors:  William J Cottrell; Anne D Paquette; Kenneth R Keymel; Thomas H Foster; Allan R Oseroff
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

10.  A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer.

Authors:  Nathalie C Zeitouni; Anne D Paquette; Joseph P Housel; Yi Shi; Gregory E Wilding; Thomas H Foster; Barbara W Henderson
Journal:  Lasers Surg Med       Date:  2013-02-06       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.